2. Disease Areas
  3. Infection
  4. Coronavirus Infection
  5. SARS-CoV-2 Infection

SARS-CoV-2 Infection

SARS-CoV-2 infection, caused by a highly transmissible single-stranded RNA betacoronavirus, leads to COVID-19 and is associated with significant neurological and neuropsychiatric manifestations during both acute and post-acute phases, including cognitive deficits, fatigue, anxiety, depression, PTSD, and sleep disturbances, with long-term risks of stroke, memory disorders, seizures, and other neurologic conditions. Emerging evidence suggests that viral structural proteins such as the spike and S1 subunit may act as pathogen-associated molecular patterns (PAMPs), triggering proinflammatory immune responses through Toll-like receptor (TLR) pathways in the periphery and brain, potentially contributing to the observed neurologic and psychiatric sequelae.

SARS-CoV-2 Infection (9):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10219
    Rapamycin 53123-88-9 99.94%
    Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant.
    Rapamycin
  • HY-113478S
    Ursodeoxycholic acid-d4 347841-46-7 99.52%
    Ursodeoxycholic acid-2,2,4,4-d4 is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection.
    Ursodeoxycholic acid-d<sub>4</sub>
  • HY-157805
    PROTAC SARS-CoV-2 Mpro degrader-2 3057294-32-0
    PROTAC SARS-CoV-2 Mpro degrader-2 (Compound 6) is a potent PROTAC degrader of SARS-CoV-2 Mpro. PROTAC SARS-CoV-2 Mpro degrader-2 has broad-spectrum antiviral activity against CoVs, including SARS-CoV-2 (EC50 = 10.8 μM), HCoV-OC43 (EC50 = 1.6 μM) and HCoV-229E (EC50 = 6.5 μM). PROTAC SARS-CoV-2 Mpro degrader-2 exhibits potent activity against SARS-CoV-2 in Calu-3 cells, with an EC50 of 0.89 μM.
    PROTAC SARS-CoV-2 Mpro degrader-2
  • HY-168457
    RNase L ligand 2 3025538-34-2
    RNase L ligand 2 (compound 6) is the Rnase L ligand part of RNAse L RIBOTAC (HY-168455), an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. RNase L ligand 2 can be used in the synthesis of RIBOTAC.
    RNase L ligand 2
  • HY-175461
    AVI-4206 3105041-48-0
    AVI-4206 is a selective Mac1 inhibitor with an lC50 of 64 nM. AVI-4206 reduces viral replication, restores an interferon response, and leads to a survival benefit in an animal model of SARS-CoV-2 infection. AVI-4206 can be used the study of SARS-CoV-2 infection.
    AVI-4206
  • HY-178445
    PI3Kδ-IN-27 3097471-25-2
    PI3Kδ-IN-27 is an PI3Kδ inhibitor with an IC50 of 355.3 nM. PI3Kδ-IN-27 exhibits anti-SARS-CoV-2 activity. PI3Kδ-IN-27 can be used for the research of infection, such as COVID-19.
    PI3Kδ-IN-27
  • HY-178439
    SARS-CoV-2 3CLpro-IN-33 2920182-91-6
    SARS-CoV-2 3CLpro-IN-33 (Compound 16) is an orally active SARS-CoV-2 3CL protease inhibitor, with an IC50 value of 1.5 nM. SARS-CoV-2 3CLpro-IN-33 shows excellent anti-SARS-CoV-2 viral activity in the HEK293T-AT cell model with an EC50 of 0.017 μM. SARS-CoV-2 3CLpro-IN-33 can be used for the study of COVID-19 infetction.
    SARS-CoV-2 3CLpro-IN-33
  • HY-178480
    SARS-CoV-2 Mpro-IN-49
    SARS-CoV-2 Mpro-IN-49 (Compound 22e) is a potent SARS-CoV-2 main protease (Mpro) inhibitor (IC50=0.087 μM). SARS-CoV-2 Mpro-IN-49 is promising for research of SARS-CoV-2 and coronavirus.
    SARS-CoV-2 Mpro-IN-49
  • HY-178435
    SARS-CoV-2 Mpro-IN-48
    SARS-CoV-2 Mpro-IN-48 is a potent SARS-CoV-2 main protease inhibitor with an IC50 of 21.1 nM. SARS-CoV-2 Mpro-IN-48 exhibits potent antiviral activity against the SARS-CoV-2 JN.1 variant. SARS-CoV-2 Mpro-IN-48 can be used for the research of infection, such as COVID-19.
    SARS-CoV-2 Mpro-IN-48